PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).

Inclusion Criteria:

• Female or male 18 years of age or older.
• Patients with a high grade primary glial tumor (Astrocytoma grade 3; Glioblastoma; Anaplastic Oligodendroglioma)
• Patients scheduled to begin radiation and/or chemotherapy.
• Able to give informed consent to participate in the research.
• Enrolled in a social security plan or beneficiary of such a plan.

Exclusion Criteria:

• Patient under guardianship or curatorship
• Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial.
• Refusal to participate.
• Pregnant or breastfeeding woman.

Female or male, 18 years of age or older, with a primary high-grade glial tumor (Astrocytoma Grade 3; Glioblastoma; Anaplastic Oligodendroglioma) who needs to initiate radiation and/or chemotherapy.